Portal de Periódicos da CAPES

Mechanisms of intranasal steroids in the management of upper respiratory allergic diseases

1999; Elsevier BV; Volume: 104; Issue: 4 Linguagem: Inglês

10.1016/s0091-6749(99)70309-x

1097-6825

Harold S. Nelson,

Respiratory and Cough-Related Research

Intranasal steroids have proved to be the most effective class of drugs in reducing the symptoms of allergic rhinitis. This clinical response reflects the broad anti-inflammatory activity that has been demonstrated for corticosteroids. Single doses of topical corticosteroids administered before nasal allergen challenge block the late-phase reaction, whereas repeated dosing with intranasal steroids blocks both the early and the late response, as well as the priming phenomenon. Nasal inflammation is accomplished through a number of effector cells and mechanisms, which in turn are produced by director cells through the release of cytokines and chemokines. The anti-inflammatory action of corticosteroids is largely effected through blocking the synthesis and release of these cytokines/chemokines.